Adverse event monitoring of antiretroviral drugs- A pharmacovigilance perspective

Authors

Rakshit Sehgal

Department of Pharmacology,
Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana
M. C. Gupta

Department of Pharmacology,
Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana
P. S. Ghalaut

Department of Medicine,
Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana

DOI:

https://doi.org/10.7439/ijpr.v7i3.3988

Keywords:

Antiretrovirals, Adverse Drug Reactions, Pharmacovigilance

Abstract

Objective: To monitor and evaluate adverse drug reactions (ADRs) to antiretroviral drugs in patients of HIV/AIDS by active and spontaneous/solicited ADR monitoring.

Methods: A prospective observational study to monitor ADRs was carried out over 12 months in 187 patients of HIV/AIDS taking antiretroviral treatment. The ADRs reported were evaluated for incidence, frequency, causality, severity, seriousness and preventability. Causality assessment was done using the WHO-UMC and Naranjo scale, seriousness was considered as per the ADR reporting form, severity and preventability assessment were done as per the Hartwig severity scale and the modified Schumock and Thornton criteria respectively.

Results: 103 patients (55.1%) reported at least one ADR and 108 ADR reports were collected. Mostly the ADRs came from the tenofovir + lamivudine + efavirenz regimen with efavirenz related to most number of ADRs (52.5%). Maximum ADRs belonged to the system organ class of neurological disorders (64.81%) followed by gastrointestinal (19.44%) and skin and appendages disorders (7.40%). Causality assessment by WHO-UMC scale revealed most of the reactions as possible (99.2%) while Naranjo scale assessed most of them as probable (69.8%). Most of the reactions (96.1%) were mild in nature and no serious reactions were reported. Preventability assessment determined most reactions (94.6%) as not preventable.

Conclusion: Antiretroviral drugs have a huge potential for causing ADRs specially neurological and gastrointestinal. Active pharmacovigilance is vital in recognizing such reactions to ensure timely management and optimal therapeutic outcomes.

Downloads

Download data is not yet available.

Published

2017-03-28

How to Cite

Sehgal R, Gupta MC, Ghalaut PS. . Int J of Pharmc Res [Internet]. 2017Mar.28 [cited 2020May29];7(3):65-70. Available from: https://ssjournals.net/index.php/ijpr/article/view/3988

Issue

Vol. 7 No. 3 (2017): Mar

Section

Research Articles

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
4. Author must Submit Copyright form After acceptance of Article